NCT01137916

Study to Evaluate Imatinib in Desmoid Tumors

Phase II Study to Evaluate Glivec (Imatinib Mesylate) to Induce Progression Arrest in Aggressive Fibromatosis / Desmoid Tumors Not Amenable to Surgical Resection With R0 Intent or Accompanied by Unacceptable Function Loss

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 39 (actual)
• Sponsor: Heidelberg University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The objective of the present study is to evaluate the activity and safety of imatinib in patients with aggressive fibromatosis who, after receiving the standard therapy, show an inoperable recurrent tumor or disease not readily controllable by surgery or radiotherapy.

Conditions

• Aggressive Fibromatosis
• Desmoid Tumor

Interventions

Type	Name	Description
DRUG	Imatinib	800 mg

Timeline

• Start date: 2010-06-01
• Primary completion: 2016-12-01
• Completion: 2016-12-01
• First posted: 2010-06-07
• Last updated: 2017-05-03

Locations

1 site across 1 country: Germany